Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 422

1.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

2.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

3.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
4.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013.

PMID:
20385246
5.

Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults.

Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, Burggren AC, Bookheimer SY, Huang SC, Barrio JR, Small GW.

Am J Geriatr Psychiatry. 2009 Jun;17(6):493-502.

6.

Psychological well-being and regional brain amyloid and tau in mild cognitive impairment.

Chen ST, Siddarth P, Saito NY, Rueda F, Haight T, Ercoli LM, Miller KJ, Lavretsky H, Barrio JR, Bookheimer SY, Small GW, Merrill DA.

Am J Geriatr Psychiatry. 2014 Apr;22(4):362-9. doi: 10.1016/j.jagp.2012.09.002.

7.

Differential FDDNP PET patterns in nondemented middle-aged and older adults.

Ercoli LM, Siddarth P, Kepe V, Miller KJ, Huang SC, Cole GM, Lavretsky H, Bookheimer SY, Kim J, Phelps ME, Barrio JR, Small GW.

Am J Geriatr Psychiatry. 2009 May;17(5):397-406. doi: 10.1097/JGP.0b013e318198750b.

8.

Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging.

Ercoli LM, Small GW, Siddarth P, Kepe V, Huang SC, Miller KJ, Lavretsky H, Bookheimer SY, Barrio JR, Silverman DH.

Int J Geriatr Psychiatry. 2012 Oct;27(10):1017-27. doi: 10.1002/gps.2816.

9.

Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease.

Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM.

Neurobiol Aging. 2010 Oct;31(10):1669-78. doi: 10.1016/j.neurobiolaging.2008.09.012.

10.

Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.

Shin J, Lee SY, Kim SH, Kim YB, Cho SJ.

Neuroimage. 2008 Nov 1;43(2):236-44. doi: 10.1016/j.neuroimage.2008.07.022.

PMID:
18694837
11.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016.

12.

2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations.

Shin J, Lee SY.

Am J Geriatr Psychiatry. 2010 Feb;18(2):187; author reply 188. doi: 10.1097/JGP.0b013e3181c29446. No abstract available.

PMID:
20104075
13.

Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Furukawa K, Okamura N, Tashiro M, Waragai M, Furumoto S, Iwata R, Yanai K, Kudo Y, Arai H.

J Neurol. 2010 May;257(5):721-7. doi: 10.1007/s00415-009-5396-8.

PMID:
19946781
14.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR.

Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.

PMID:
11790632
15.

Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia.

Merrill DA, Siddarth P, Saito NY, Ercoli LM, Burggren AC, Kepe V, Lavretsky H, Miller KJ, Kim J, Huang SC, Bookheimer SY, Barrio JR, Small GW.

Int Psychogeriatr. 2012 Jul;24(7):1076-84. doi: 10.1017/S1041610212000051.

16.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

17.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

18.

Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.

Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, Bookheimer SY, Miller KJ, Kim J, Lavretsky H, Huang SC, Barrio JR.

Arch Neurol. 2012 Feb;69(2):215-22. doi: 10.1001/archneurol.2011.559.

19.

The merits of FDDNP-PET imaging in Alzheimer's disease.

Shin J, Kepe V, Barrio JR, Small GW.

J Alzheimers Dis. 2011;26 Suppl 3:135-45. doi: 10.3233/JAD-2011-0008. Review.

PMID:
21971458
20.

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Sep;50(9):1464-70. doi: 10.2967/jnumed.109.064360.

Items per page

Supplemental Content

Support Center